Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $33.55 USD
Change Today +0.82 / 2.51%
Volume 7.6M
BAX On Other Exchanges
SIX Swiss Ex
As of 8:04 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - $43.44
52 Week Low
10/2/15 - $32.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX) Key Developments

Baxter International Inc. Names Munib Islam to the Board

Baxter International Inc. announced it has reached an agreement with Third Point LLC to appoint Munib Islam to its Board of Directors immediately and add another, mutually agreed upon independent director in the near-term. Mr. Islam, a Partner at Third Point, will serve on the board’s executive search working group and audit committee. The company’s board will increase to 12 members with the addition of the two new directors. Mr. Islam is a partner at Third Point, where he leads equity research, and sits on the firm’s Risk Committee. Mr. Islam previously worked at Highbridge Capital, where he was a Managing Director and the Portfolio Manager of the Highbridge European Value Equities fund. Earlier in his career, Mr. Islam worked at the Oak Hill Capital and as an investment banker at Lazard LLC.

Baxter International Inc. Presents at 12th Annual Goldman Sachs European Medtech and Healthcare Services Conference, Sep-09-2015 11:30 AM

Baxter International Inc. Presents at 12th Annual Goldman Sachs European Medtech and Healthcare Services Conference, Sep-09-2015 11:30 AM. Venue: London, United Kingdom.

Takeda to expand rights related to Nanotherapeutics’ Vero cell technology platform

Takeda Pharmaceutical has entered into an agreement to acquire expanded commercialization and technology access rights related to Nanotherapeutics' Vero cell technology platform, a cell culture-based platform for vaccine production. Nanotherapeutics acquired Vero cell technology from Baxalta, formerly Baxter International's BioScience division.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $33.55 USD +0.82

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $154.55 USD +5.55
Mylan NV $43.66 USD +2.25
St Jude Medical Inc $63.81 USD +1.05
Toray Industries Inc ¥1,065 JPY +9.00
Zimmer Biomet Holdings Inc $95.27 USD +1.31
View Industry Companies

Industry Analysis


Industry Average

Valuation BAX Industry Range
Price/Earnings 10.6x
Price/Sales 1.1x
Price/Book 2.3x
Price/Cash Flow 8.4x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at